IL-34 Mimetic Screening via BMP Binding for Bone Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for excessive osteolysis and osteoporosis, such as calcitonin, monoclonal antibodies, and bisphosphonates, have significant side effects and limited efficacy, while BMP-2 treatments are expensive and require supraphysiological concentrations, posing risks of inflammation and abnormal bone formation.
Innovation Solution
A method to screen for molecules that mimic IL-34's bone regulation activity by binding to BMPs, inhibiting osteoclast formation, and promoting osteoblast differentiation, using a screening process that involves reacting candidate molecules with BMPs, detecting binding, and selecting those that induce osteoblast activities without activating osteoclast functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BMP-2 is used to treat bone defects, then bone regeneration is promoted, but the treatment is expensive and requires supraphysiological concentrations causing side effects like inflammation and abnormal bone formation
Solution Approach 1:
The patent uses IL-34 as an intermediary molecule that binds to BMP-2 and modulates its activity. This intermediary approach allows the system to achieve bone regeneration effects while reducing the harmful supraphysiological concentrations of BMP-2, thereby resolving the contradiction between efficacy and harmful effects
Solution Approach 2:
The patent changes the concentration parameter of BMP-2 from supraphysiological to physiological levels by using IL-34 as a modulator. This parameter change maintains bone regeneration efficacy while eliminating the harmful side effects associated with high concentrations
2Reliability
If calcitonin is used to inhibit osteoclast formation, then osteolysis is reduced, but chronic exposure leads to loss of inhibitory effects through down regulation of calcitonin receptor expression
Solution Approach 1:
The patent employs IL-34 as an intermediary that provides sustained inhibition of osteoclast formation without the down-regulation problem of calcitonin. IL-34 binds to BMP-2 and maintains inhibitory effects on osteoclasts over time, resolving the contradiction between initial efficacy and duration of action
3Reliability
If monoclonal antibodies are used to block osteolysis, then osteoclast activity is inhibited, but the treatment can induce immune responses in patients
Solution Approach 1:
The patent uses IL-34 as a natural intermediary molecule that inhibits osteoclast activity without triggering immune responses. By using a physiological cytokine rather than monoclonal antibodies, the system achieves osteoclast inhibition while avoiding the harmful immune response side effect
4Reliability
If bisphosphonates are used to inhibit osteoclast activity, then excessive osteolysis is reduced, but the treatment causes gastrointestinal discomfort and poor absorption
Solution Approach 1:
The patent employs IL-34 as an intermediary that inhibits osteoclast activity through a different mechanism that does not require gastrointestinal absorption. This resolves the contradiction between osteoclast inhibition efficacy and gastrointestinal tolerability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method identifies molecules that effectively regulate bone remodeling by enhancing osteoblast differentiation and reducing osteoclast activity, offering a safer and more effective alternative to existing treatments.
Implementation Method 1
A method of screening for a molecule having bone regulation activity based on the binding of interleukin-34 to bone morphogenetic proteins
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to a method of screening for a molecule mimicking interleukin 34 (IL-34) bone regulation activity based on the binding of IL-34 to bone morphogenetic proteins (BMPs), which comprises the steps of: 1) reacting a candidate molecule and BMPs under suitable conditions, 2) detecting the binding of the candidate molecule to BMPs and optionally a bone regulation activity, 3) comparing the binding and optionally the bone regulation activity detected in step 2) to a control, and 4) selecting a molecule capable of binding to BMPs and inducing osteoblast differentiation and activities without activating osteoclast functions. The present invention also relates to a molecule mimicking IL-34 bone regulation activity based on the binding of IL-34 to BMPs, obtained by the method, and to a pharmaceutical composition comprising the molecule and a pharmaceutically acceptable carrier.